Characteristics | F | C | A | D | G | E | H | B | P |
---|---|---|---|---|---|---|---|---|---|
No. patients | 58 | 85 | 92 | 122 | 144 | 157 | 224 | 255 | |
Age, yrs | 57.2 ± 13.4 (58) | 50.7 ± 18.4 (85) | 54.3 ± 19.4 (91) | 50.7 ± 17.1 (122) | 51.3 ± 14.6 (143) | 59.9 ± 13.8 (157) | 55.0 ± 16.8 (224) | 44.0 ± 15.5 (255) | ≤ 0.001 (51.0–53.0) |
Female | 43/58 (74.1) | 59/85 (69.4) | 70/86 (81.4) | 80/117 (68.4) | 114/143 (79.7) | 97/157 (61.8) | 156/221 (70.6) | 203/252 (80.6) | ≤ 0.001 |
Symptom duration,days | 228.3 ± 114.1 (58) | 159.7 ± 97.3 (85) | 226.0 ± 568.6 (91) | 187.7 ± 100.0 (122) | 213.6 ± 93.4 (143) | 153.3 ± 93.0 (157) | 181.5 ± 197.9 (224) | 181.3 ± 112.1 (255) | 0.044 (174.7–198.4) |
No. comorbidities | 3.2 ± 2.0 (58) | 2.2 ± 2.2 (85) | 2.5 ± 2.0 (91) | 2.1 ± 2.1 (122) | 2.9 ± 2.3 (143) | 1.7 ± 1.6 (157) | 2.9 ± 2.2 (224) | 2.2 ± 1.9 (255) | ≤ 0.001 (2.3–2.5) |
Erosions on radiographs of hands or feet | 12/39 (30.8) | 50/74 (67.6) | 7/51 (13.7) | 20/95 (21.1) | 29/140 (20.7) | 52/139 (37.4) | 45/169 (26.6) | 46/214 (21.5) | ≤ 0.001 |
RF+ | 23/33 (69.7) | 40/83 (48.2) | 40/68 (58.8) | 83/117 (70.9) | 127/139 (91.4) | 50/153 (32.7) | 122/202 (60.4) | 92/241 (38.2) | ≤ 0.001 |
ACPA+ | 22/46 (47.8) | 20/61 (32.8) | 28/46 (60.9) | 85/105 (81.0) | 83/140 (59.3) | 53/113 (46.9) | 19/71 (26.8) | 116/213 (54.5) | ≤ 0.001 |
Meets ACR/EULAR RA classification criteria | 20/22 (90.9) | 53/65 (81.5) | 47/49 (95.9) | 108/109 (99.1) | 134/139 (96.4) | 97/117 (82.9) | 130/146 (89.0) | 192/213 (90.1) | ≤ 0.001 |
HAQ (0–3) | 1.0 ± 0.8 (58) | 0.9 ± 0.7 (85) | 0.8 ± 0.7 (92) | 1.0 ± 0.7 (120) | 0.9 ± 0.7 (143) | 0.8 ± 0.6 (157) | 1.1 ± 0.7 (224) | 0.9 ± 0.7 (255) | 0.004 (0.9–1.0) |
DAS28 baseline visit | 4.6 ± 1.3 (58) | 4.3 ± 1.5 (85) | 4.8 ± 1.2 (92) | 4.2 ± 1.3 (121) | 4.0 ± 1.4 (143) | 4.9 ± 1.3 (157) | 4.3 ± 1.4 (224) | 4.8 ± 1.4 (255) | ≤ 0.001 (4.4–4.6) |
Smoking status | |||||||||
Never | 22/58 (37.9) | 38/85 (44.7) | 34/86 (39.5) | 31/116 (26.7) | 62/143 (43.4) | 56/152 (36.8) | 101/221 (45.7) | 150/252 (59.5) | ≤ 0.001 |
Formerly | 24/58 (41.4) | 23/85 (27.1) | 31/86 (36.0) | 52/116 (44.8) | 57/143 (39.96) | 71/152 (46.7) | 88/221 (39.8) | 62/252 (24.6) | |
Current | 12/58 (20.7) | 24/85 (28.2) | 21/86 (24.4) | 33/116 (28.4) | 24/143 (16.8) | 25/152 (16.4) | 32/221 (14.5) | 40/252 (15.9) | |
Education | |||||||||
High school or less | 28/56 (50.0) | 42/84 (50.0) | 47/84 (56.0) | 61/114 (53.5) | 57/136 (41.9) | 102/146 (69.9) | 101/218 (46.3) | 74/238 (31.1) | ≤ 0.001 |
Beyond high school | 28/56 (50.0) | 42/84 (50.0) | 37/84 (44.0) | 53/114 (46.5) | 79/136 (58.1) | 44/146 (30.1) | 117/218 (53.7) | 164/238 (68.9) | |
DAS28 change 0–6 mos | −1.12 ± 1.57 | −1.63 ± 1.80 | −1.09 ± 1.34 | −1.56 ± 1.48 | −1.17 ± 1.33 | −1.79 ± 1.68 | −2.09 ± 1.72 | −1.82 ± 1.70 | ≤ 0.001 (−1.74 – −1.52) |
Proportion in DAS28 remission at 6 mos | 15/44 (34.1) | 31/60 (51.7) | 14/57 (24.6) | 53/105 (50.5) | 56/115 (48.7) | 34/102 (33.3) | 91/141 (64.5) | 68/171 (39.8) | ≤ 0.001 |
DAS28 change 0–12 mos | −1.37 ± 1.78 | −1.53 ± 1.77 | −1.50 ± 1.66 | −1.80 ± 1.40 | −1.37 ± 1.32 | −2.10 ± 1.50 | −2.27 ± 1.67 | −2.27 ± 1.85 | ≤ 0.001 (−2.02– −1.76) |
Proportion in DAS28 remission at 12 mos | 14/40 (35.0) | 16/31 (51.6) | 18/50 (36.0) | 53/88 (60.2) | 54/98 (55.1) | 33/72 (45.8) | 82/110 (74.5) | 84/146 (57.5) | ≤ 0.001 |
Proportion in DAS28 remission at last visit if not in remission at baseline visit | 14/39 (35.9) | 12/25 (48.0) | 17/49 (34.7) | 49/79 (62.0) | 43/86 (50.0) | 32/69 (46.4) | 74/99 (74.7) | 78/136 (57.4) | ≤ 0.001 |
ACR/EULAR: American College of Rheumatology/European League Against Rheumatism; HAQ: Health Assessment Questionnaire Disability Index; DAS28: Disease Activity Score in 28 joints; RF: rheumatoid factor; ACPA: anticitrullinated protein antibody; RA: rheumatoid arthritis.